1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Iron Deficiency Anemia - Pipeline Review, H1 2016

Iron Deficiency Anemia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 71 pages

Iron Deficiency Anemia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Iron Deficiency Anemia - Pipeline Review, H1 2016’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
- The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects
- The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Iron Deficiency Anemia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Iron Deficiency Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Iron Deficiency Anemia - Overview 8
Pipeline Products for Iron Deficiency Anemia - Comparative Analysis 9
Iron Deficiency Anemia - Therapeutics under Development by Companies 10
Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes 11
Iron Deficiency Anemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Iron Deficiency Anemia - Products under Development by Companies 15
Iron Deficiency Anemia - Products under Investigation by Universities/Institutes 16
Iron Deficiency Anemia - Companies Involved in Therapeutics Development 17
Johnson and Johnson 17
Novartis AG 18
Panion and Bf Biotech Inc 19
Rockwell Medical, Inc. 20
Shield Therapeutics Plc 21
Vifor Pharma AG 22
Iron Deficiency Anemia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
CSJ-137 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ferric carboxymaltose - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ferric citrate - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
ferric maltol - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ferric pyrophosphate citrate - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
JNJ-42905343 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
NSC-8679 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Proteins to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
PRS-080 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Iron Deficiency Anemia - Recent Pipeline Updates 47
Iron Deficiency Anemia - Dormant Projects 63
Iron Deficiency Anemia - Product Development Milestones 64
Featured News and Press Releases 64
Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA 64
Dec 18, 2015: Shield Therapeutics announces receipt of a positive opinion from the CHMP recommending the approval of Feraccru for the treatment of iron deficiency anemia 64
Dec 01, 2015: Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference 65
Nov 30, 2015: Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement 65
Oct 28, 2015: Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology Meeting November 2015 65
Oct 06, 2015: Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology Clinical Meeting November 2015 66
Sep 09, 2015: Rockwell Medical Announces the U.S. Commercial Launch of Triferic 67
Jul 15, 2015: Rockwell Medical Announces Triferic Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation 67
Jul 13, 2015: Rockwell Medical Announces Triferic ESA-Sparing PRIME Study Published in Kidney International 68
May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for Iron Deficiency Anemia, H1 2016 8
Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Iron Deficiency Anemia - Pipeline by Johnson and Johnson, H1 2016 17
Iron Deficiency Anemia - Pipeline by Novartis AG, H1 2016 18
Iron Deficiency Anemia - Pipeline by Panion and Bf Biotech Inc, H1 2016 19
Iron Deficiency Anemia - Pipeline by Rockwell Medical, Inc., H1 2016 20
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H1 2016 21
Iron Deficiency Anemia - Pipeline by Vifor Pharma AG, H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Iron Deficiency Anemia Therapeutics - Recent Pipeline Updates, H1 2016 47
Iron Deficiency Anemia - Dormant Projects, H1 2016 63

List of Figures
Number of Products under Development for Iron Deficiency Anemia, H1 2016 8
Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Targets, H1 2016 24
Number of Products by Stage and Targets, H1 2016 24
Number of Products by Mechanism of Actions, H1 2016 26
Number of Products by Stage and Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N Sulphoglucosamine Sulphohydrolase ...

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.